Avantor, Inc. (NYSE:AVTR) Shares Purchased by MassMutual Private Wealth & Trust FSB

MassMutual Private Wealth & Trust FSB grew its stake in shares of Avantor, Inc. (NYSE:AVTR) by 99.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,253 shares of the company’s stock after acquiring an additional 625 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Avantor were worth $26,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. UMB Bank n.a. acquired a new position in shares of Avantor during the 3rd quarter worth approximately $49,000. Nisa Investment Advisors LLC boosted its stake in Avantor by 69.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after buying an additional 835 shares during the last quarter. GAMMA Investing LLC grew its holdings in Avantor by 89.9% in the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after buying an additional 1,285 shares during the period. Livforsakringsbolaget Skandia Omsesidigt increased its stake in shares of Avantor by 278.0% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock valued at $130,000 after acquiring an additional 3,700 shares during the last quarter. Finally, ORG Wealth Partners LLC purchased a new position in shares of Avantor during the 3rd quarter worth about $139,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AVTR has been the subject of several research analyst reports. Wells Fargo & Company dropped their price target on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, October 28th. Barclays lowered their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Raymond James cut their price objective on Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a report on Tuesday, January 21st. UBS Group reiterated a “neutral” rating and set a $25.00 target price (down previously from $29.00) on shares of Avantor in a report on Friday, January 17th. Finally, Robert W. Baird cut their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $27.38.

Avantor Stock Up 0.9 %

AVTR stock opened at $22.07 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. The firm has a 50 day simple moving average of $21.50 and a 200-day simple moving average of $23.39. The company has a market capitalization of $15.02 billion, a P/E ratio of 47.97, a PEG ratio of 3.53 and a beta of 1.28. Avantor, Inc. has a twelve month low of $19.59 and a twelve month high of $28.00.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.